Lung neoplasm malignant

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
3 Unique sponsors
6 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 3
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 2 substances
Checkpoint inhibitor (PD-1) 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Unknown / small molecule 1 substance
Kinase inhibitor 1 substance
Phase II: 3 Phase I: 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

3 trials
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN; PEMBROLIZUMAB
    2024-515772-12-00 5 countries 2025 n=61
    Ended
  • Academisch Ziekenhuis Maastricht Academic
    BEVACIZUMAB; SACITUZUMAB GOVITECAN
    2024-514066-40-00 1 country 2025 n=25
    Recruiting
  • Academisch Ziekenhuis Maastricht Academic
    FEBUXOSTAT; OSIMERTINIB
    2025-523033-26-00 1 country n=14
    Pending

Phase I

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-517746-34-00 1 country n=36
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Academisch Ziekenhuis Maastricht Academic 2 Phase II 1
Novartis Pharma AG Commercial 1 Phase I 0
Merck Sharp & Dohme LLC Commercial 1 Phase II 0
New trials by year
2025
2
← All indication landscapes